Navigation Links
VentiRx Pharmaceuticals Appoints James Kyle Bryan, M.D. as Chief Medical Officer
Date:4/23/2013

SEATTLE, April 23, 2013 /PRNewswire/ -- VentiRx Pharmaceuticals, Inc. today announced the appointment of James Kyle Bryan , M.D. as Chief Medical Officer.  A hematologist and medical oncologist, Dr. Bryan brings more than 20 years of oncology drug discovery and development experience in the pharmaceutical and biotechnology industry to VentiRx.  This includes extensive operational and strategic leadership work in his previous roles as Vice President of Global Product Development at PPD, Inc., a global contract research organization, and as Vice President of Medical Affairs at Seattle Genetics.

(Logo:  http://photos.prnewswire.com/prnh/20120828/SF63676LOGO)

"Kyle will be integral in directing our clinical development efforts, which will  include our ongoing randomized, placebo-controlled Phase 2 trial of VTX-2337 in combination with pegylated liposomal doxorubicin in patients with recurrent or persistent ovarian cancer and our upcoming Phase 2 trial of VTX-2337 in head and neck cancer patients," said Robert Hershberg , M.D., Ph.D., Chief Executive Officer of VentiRx. "His extensive experience in oncology drug development combined with his strong connections to oncology thought leaders will be invaluable to VentiRx going forward.  We are delighted to have him join the VentiRx team."

Board-certified in medical oncology, hematology and internal medicine, Dr. Bryan currently serves on the clinical faculty of medicine for hematology and oncology at the University of Washington Medical Center.  Dr. Bryan received a B.S. in biochemistry and an M.D. from Louisiana State University and completed his fellowship in hematology and oncology at the University of Washington.

About VentiRx Pharmaceuticals
VentiRx Pharmaceuticals Inc. is a clinical stage biopharmaceu
'/>"/>

SOURCE VentiRx Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Aurigenes Collaboration Programs with Endo Pharmaceuticals Reach Important Milestones
2. Vanda Pharmaceuticals Appoints Dr. Paolo Baroldi As Chief Medical Officer
3. Next Silicon Valley BioTalks Tackles “Is EDC Becoming a Commodity?” at Onyx Pharmaceuticals HQ
4. Global Nuclear Medicine / Radiopharmaceuticals Market worth $5.55 Billion by 2017
5. US Radiopharmaceuticals (USR) Awards Contract to Von Gahlen International for New Technetium-99m Generator Production Line Using Low Enriched Uranium Molybdenum-99
6. Anthera Pharmaceuticals Reports 2012 Fourth Quarter And Fiscal Year Financial Results
7. Savient Pharmaceuticals Reports Fourth Quarter and Year-End 2012 Financial Results
8. New Opportunity: The Biomedical Innovations of Tomorrow - Research Report on PhotoMedex, Axiall Corp, Varian Medical Systems, Volcano Corporation and Navidea Biopharmaceuticals
9. Keryx Biopharmaceuticals to Present at the 25th Annual ROTH Conference
10. Regeneron Pharmaceuticals’ Industrial Operations & Product Supply Site Receives International Recognition for Operational Excellence
11. Leica Biosystems and Synthon Biopharmaceuticals Partner to Develop a Companion Diagnostic Program for Targeted Cancer Therapies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... Research and Markets ( http://www.researchandmarkets.com/research/v6klp2/nanobiotechnology ... PharmaBiotech,s new report "Nanobiotechnology Applications, Markets ... An increasing use of nanobiotechnology ... anticipated. Nanotechnology will be applied at all ... for optimal delivery to diagnostic applications in ...
(Date:9/2/2015)... , Sep. 02, 2015 ... has announced the addition of Jain PharmaBiotech,s new ... to their offering. This report ... a characteristic that can be objectively measured and ... pathogenic processes as well as pharmacological responses to ...
(Date:9/2/2015)... , Sept. 2, 2015  Neurotech Pharmaceuticals, ... enrolled in the multicenter Phase 2 clinical trial ... long-term treatment of recurrent subfoveal choroidal neovascularization secondary ... is a unique vascular endothelial growth factor (VEGF) ... implant. "This landmark proof-of-concept study will ...
(Date:9/2/2015)... , September 2, 2015 BiondVax ... of the National Institute of Allergy and Infectious Diseases (NIAID), ... the Department of Health and Human Services (HHS), to launch ... the United States in the 2015-16 timeframe. ... vaccine candidate, Multimeric-001 (M-001), as a primer vaccine, which would ...
Breaking Biology Technology:Global Nanobiotechnology Applications, Markets and Companies Report 2015-2024 2Global Nanobiotechnology Applications, Markets and Companies Report 2015-2024 3Updated 2015 Biomarkers Report - Latest Technologies, Markets and Companies Insights to 2024 with over 1,000 References 2Updated 2015 Biomarkers Report - Latest Technologies, Markets and Companies Insights to 2024 with over 1,000 References 3Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 2Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 3Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 4BiondVax Announces Intent to Launch a Phase 2 Trial in the United States in Collaboration with the U.S. National Institutes of Health 2BiondVax Announces Intent to Launch a Phase 2 Trial in the United States in Collaboration with the U.S. National Institutes of Health 3
... Technology and the Radboud University Nijmegen in The Netherlands ... a permanent magnet at room temperature. The results are ... and detectors. In particular graphite could be a promising ... online on 4 October in Nature Physics . ...
... 2 CardioGenics Holdings Inc. (OTC Bulletin Board: JAGH) ... ("Gilford"), pursuant to which Gilford will provide investment banking ... Group. Kenneth Sorensen, PhD, Nickolay Kukekov, PhD, and Ted ... the investment banking efforts. Drs. Sorensen, Kukekov, and Mr. ...
... BEIJING, China, Oct. 2 /PRNewswire-Asia-FirstCall/ -- Yongye International,Inc. ... leading manufacturer,developer and distributor of Shengmingsu brand plant and ... today announced its 2010-,2012 strategic plan. , ... 2008 and thus far in,2009, Yongye expects to achieve ...
Cached Biology Technology:Graphite mimics iron's magnetism 2CardioGenics Holdings Inc. Engages Gilford Securities As Investment Banker 2Yongye International Announces 2010-2012 Strategic Plan 2Yongye International Announces 2010-2012 Strategic Plan 3Yongye International Announces 2010-2012 Strategic Plan 4Yongye International Announces 2010-2012 Strategic Plan 5
(Date:8/10/2015)... Germany , August 10, 2015 /PRNewswire/ ... world leader in Eye Tracking Technology for more than ... Eye Tracking Platform for integration into all consumer display ... designs for seamless integration of eye tracking into consumer ... and augmented reality smart glasses. Omnivision,s leading sensor technology ...
(Date:8/6/2015)... Germany , August 6, 2015 ... (SMI) shows the world,s first Eye Tracking ... Epson,s Moverio BT-200 see-through head mounted display and on ... unprecedented quality and efficiency is brought to personalized visualization ... the first time, professionals and researchers can integrate gaze, ...
(Date:8/5/2015)... Transparency Market Research has released ... Global Industry Analysis, Size, Share, Growth, Trends and Forecast ... is forecast to reach US$ 2,671.8 Mn by 2022. ... systems by civil and government agencies. This is majorly ... activities across the globe that would elevate the demand ...
Breaking Biology News(10 mins):SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 3SMI Shows First Eye Tracking Upgrade for Augmented Reality Glasses 2SMI Shows First Eye Tracking Upgrade for Augmented Reality Glasses 3Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 2Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 3Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 4Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 5Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 6
... Western Reserve University School of Medicine, has received a ... One of 17 awardees to receive this ... where the biological features and disease risk of an ... the genetics of ancestral generations as on their own ...
... 15 cm long lionfish in Fish Bay along the southern coast ... of the invasive fish in the Virgin Islands National Park. ... the following day within 10 meters of the original sighting. A ... Ocean Science and the National Park Service were in the area ...
... parties and junior cooking classes can help increase vegetable intake ... journal Nutrition & Dietetics . Researchers at ... vegetables children ate improved after they took part in a ... Twenty six kindergarten children aged four to five participated ...
Cached Biology News:Case Western Reserve geneticist receives prestigious NIH Director's Pioneer Award 2NOAA divers capture invasive lionfish in the Virgin Islands National Park 2New research: Children's vegetable intake linked to Popeye cartoons 2